About the Author

Dr. Villamil-Gomez is an attending physician in infectious diseases at the Hospital Universitario de Sincelejo and Clínica Santa María, Sincelejo, Sucre, Colombia. His primary research interests include tropical diseases, such as dengue, chikungunya, Zika, and Mayaro viruses; leishmaniasis and Chagas disease; and travel medicine.

References

Address for correspondence: Alfonso J. Rodriguez-Morales, Public Health and Infection Research Group and Incubator, Office 14-315, Scientific Research Direction, Fl 3, Bldg 14, Department of Community Medicine, School of Medicine, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Sector La Julita, Pereira 660003, Risaralda, Coffee-Triangle Region, Colombia; email: arodriguezm@utp.edu.co

Oropouche Fever—Associated Aseptic Meningoencephalitis, Southeastern Brazil

Sebastian Vernal, Camila C.R. Martini, Benedito A.L. da Fonseca

Author affiliation: University of São Paulo, Ribeirão Preto, Brazil

DOI: https://doi.org/10.3201/eid2502.181189

Oropouche fever is a neglected arthropodborne disease and zoonosis responsible for several outbreaks of a febrile disease in Central and South America. We present a clinical case of aseptic meningoencephalitis in an immunocompetent patient that resulted from Oropouche virus acquired in northern Brazil but diagnosed in a nonendemic region.
In April 2016, a 28-year-old man (S.V.) in Ribeirão Preto, southeastern Brazil, with a history of Gilbert syndrome sought care for a sudden high fever, severe 1-sided headache, vomiting, intense photophobia, stiff neck, and confusion. Seventeen days earlier, he had returned from a trip to Mosqueiro Island in northern Brazil; he received yellow fever vaccine 5 days before traveling. His 1-week visit to the island included outdoor activities that involved entrances into the native Amazon rainforest. The patient returned to Ribeirão Preto and remained asymptomatic for 10 days before becoming acutely ill with fever, chills, myalgia, headache, and dizziness. Symptoms occurred intermittently for 3 days, which prompted him to seek medical care. After evaluation, a diagnosis of dengue fever was considered. Microhematocrit was 54%, and tourniquet test was negative. Nonstructural protein (NS) 1 antigen detection test was requested, and the patient was treated with medications for his symptoms and prescribed abundant oral hydration and bed rest. Dengue fever was ruled out because NS1 antigen detection and IgM serologic testing provided negative results 6 days after initial symptom onset. Therefore, he was referred to an infectious disease outpatient clinic at another healthcare facility for further investigation. Yellow fever vaccine reaction and malaria were initially the main hypotheses, but thick blood film examination results were negative.

Seven days after initial symptom onset, the patient’s headache worsened and became left-sided and pulsatile; intense photophobia, vomiting, and fever (105.8°F) developed. No hemorrhagic manifestations were observed. He was admitted to the emergency department at the Teaching Hospital in Ribeirão Preto with nuchal rigidity; ceftriaxone was initiated.

At admission, he was confused, including attention deficits and hallucinations. Physical examination found tachypnea (27 breaths/min), heart rate 76 beats/min, and blood pressure 130/80 mm Hg; cardiopulmonary examination results were unremarkable, and the liver was palpable at 3 cm under the costal margin (spleen was not palpable) with no pain at abdominal palpation. The patient exhibited mild spasticity of lower limbs with positive Babinski sign, without focalities at neurologic exam. Because of clinical examination findings, viral meningoencephalitis emerged as a possible diagnosis, and intravenous acyclovir was started.

Laboratory examination showed complete blood counts within reference ranges (hematocrit 44%; leukocytes 10,300 cells/mm³ [no left shift; lymphocytes 2,300 cells/mm³]; platelets 388,000/mm³), normal kidney function, and sodium and potassium concentrations within reference ranges. Liver enzymes were slightly elevated (aspartate aminotransferase 30 U/L [reference 15–46 U/L], alanine aminotransferase 71 U/L [reference 13–69 U/L], γ-glutamyl transferase 107 U/L [7–60 U/L]); total bilirubin was 0.73 mg/dL (reference 0.2–1.0 mg/dL).

Serologic test results were nonreactive for hepatitis A, B, and C; HIV; syphilis; Epstein-Barr virus; Toxoplasma gondii; and Trypanosoma cruzi. Thorax radiograph imaging was unremarkable; cerebral computed tomography scan showed cortical edema on the left frontal lobe (Figure, panel A).

Results of a spinal tap showed a 23 cm H₂O opening pressure (reference 5–20 cm H₂O) with clear cerebrospinal fluid containing 45 cells/mm³ (reference <5 cells/mm³) (85% lymphocytes); protein concentration of 53 mg/dL (reference <45 mg/dL); and glucose concentration of 62 mg/dL (capillary 100 mg/dL [reference 2/3 of capillary glucose]). VDRL test results were negative, and bacterial and fungal antigens were not detected. PCR results were negative for enterovirus, herpes viruses 1 and 2, varicella zoster virus, cysticercosis, tuberculosis, and toxoplasmosis but positive for Oropouche virus (OROV) (fraction S) (1). Blood sample PCR results were also positive for OROV (Figure, panel B) (2), and indirect immunofluorescence antibody testing (Appendix, Figure).

After 7 days of hospitalization, the patient recovered all neurologic function with no sequelae (posttreatment electromyography and magnetic resonance imaging findings were unremarkable). He was discharged and has had no additional relapses.

OROV, an RNA virus belonging to the genus Orthobunyavirus, family Peribunyaviridae, is the causative agent of Oropouche fever in humans (4). In a sylvatic cycle, OROV can be transmitted to some animals by mosquitoes and in an urban environment can be transmitted to humans by the midge Culicoides paraensis (5). Usually, humans become infected in forested areas and then can translocate the virus to an urban environment (6).

After a 4- to 8-day incubation period, fever, headache, myalgia, arthralgia, chills, photophobia, dizziness, nausea, and vomiting develop (2,6). Less frequently, patients experience rash, anorexia, retro-orbital pain, and general malaise (2,6,7). Hemorrhagic phenomena also have been described (8). Most patients recover spontaneously after 7 days, although some experience symptoms for as long as 1 month (2,6,7). Some cases can relapse after recovery; the clinical picture is similar to the initial onset or can be more severe, including aseptic meningitis (9,10). These patients may experience neck stiffness, dizziness, vomiting, lethargy, diplopia, and nystagmus, but prognosis without sequel is usually good (10).

There has been an increased concern that Oropouche fever, endemic in northern Brazil, might spread across the country by contiguous urban cycles and by human movement. Physicians working worldwide in areas to which OROV is not endemic should include this neglected disease in the differential diagnosis of acute febrile syndrome, especially in patients visiting high-risk areas for OROV transmission.

Acknowledgments
We thank the medical and nursing staff of the infectious diseases ward, Teaching Hospital, Ribeirão Preto Medical School, University of São Paulo.

About the Author
Dr. Vernal, the patient in this report, is a Chilean medical doctor working with neglected diseases in Brazil since 2013 and a PhD student in clinical medicine and a medical resident of infectious disease at University of São Paulo. His primary research interests include tropical infectious diseases with special emphasis on leprosy and tegumentary leishmaniasis.

References

Address for correspondence: Benedito A.L. da Fonseca, Ribeirão Preto Medical School, University of São Paulo, 3900 Bandeirantes Av, Ribeirão Preto, SP 14049-900, Brazil; email: baldfons@fmrp.usp.br
Oropouche Virus–Associated Aseptic Meningoencephalitis, Southeastern Brazil

Appendix

Appendix Figure. Indirect immunofluorescence (IIF) antibody test results for a 28-year-old man with Oropouche virus (OROV) infection, southeastern Brazil. IIF was performed using anti-human IgG conjugated with Fluorescein isothiocyanate. A) Vero cells and anti-OROV serum (negative control). B) Vero cells plus OROV and anti-OROV serum (positive control). C) Patient’s serum sample and anti-OROV serum. Original magnification ×40.